NOVEL RESPIRABLE RIFAMPICIN-CURCUMIN LOADED NANOPARTICLES AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION

MARTINENA C.; PALMAS L.; ALARCON L.; MARTIN C.; DONNOLI L. ; RIEMER C.; RIEDEL J.; MORELLI P.; PELLEGRINI J.; AMIANO N.; BERNABEU E.; GARCIA V.; CHIAPPETTA D.A.; MORETTON M.A.; TATEOSIAN N.

CABA

Congreso; REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2020; 2020

Rifampicin (RIF) is one of the most powerful and effective first line drug employed in the treatment of Mycobacterium tuberculosis (Mtb) infection. With the worldwide emergence of highly drug-resistant tuberculosis (TB), novel agents that have direct antimycobacterial effects or that enhance host immunity are urgently needed. It was described the immunomodulatory anti-TB effects of Curcumin (CUR), a potent anti-oxidant and apoptosis inducer compound. We develop novel RIF-CUR nanoparticles (RIF-CUR NP) with improved drug aqueous solubility and stability for inhalator administration. Then, we analyzed by confocal microscopy the in vitro uptake of CUR-NP (20 μg/ml) in human macrophages (derived from PBMCs) at different time points (1h, 18h, 24h and 48h). We found a higher drug cellular uptake levels (intensity/ area) for Mtb antigen-stimulated cells (0.25±0.04) than unstimulated control (0.07±0.02) over 18 hours (ANOVA test, p